The Company has conducted extensive scientific research for a decade leading to breakthroughs in understanding the KB Clay's bioactivity and material's composition. Kisolite Corp continues to invest in research and development to expand and support the field of use opportunities for Kisolite.
The company's internal R&D activities are overseen by Drs. Neil Branda and Dirk Lange at 4D LABS in Burnaby, British Columbia, Canada. Initiated in 2021, pre-clinical development has been conducted by Althea DRF Lifesciences at their FDA certified facilities under the direction of Kisolite Corp's scientific team.
In partnership with Althea DRF Lifesciences, the Company's in-house science team has focused on studies for dermatology. The results show that Kisolite demonstrates strong efficacy in the treatment of dermatological disorders, particularly acne, psoriasis and atopic dermatitis in the pharmaceutical sector and offers numerous skin health product development opportunities in the consumer health sector.
Research validations result in a characterized, standardized, safe, GLP-compliant compound for pharmaceutical and consumer health industry partners.
OUR DERMATOLOGY SUITE
The pre-clinical studies evaluated 20 therapeutic areas for Kisolite and the results have shown significant therapeutic benefits across a spectrum of dermatological markets.
In addition to further clinical studies in pharma dermatology and in consumer health, Kisolite Corp will further advance its research work in therapeutic areas such as inflammatory conditions.